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Abstract
Objective: We have previously shown that cholesterol diet-induced hyperlipidemia (marked hypertriglyceridemia and moderate
hypercholesterolemia) increases cardiac formation of peroxynitrite and results in a moderate cardiac dysfunction in rats. Here our aim
was to further clarify the mechanism of hyperlipidemia-induced nitrosative stress in a transgenic mouse model and to test if high cholesterol
or high triglyceride is responsible for the hyperlipidemia-induced cardiac dysfunction.
Methods and results: To determine the effect of cholesterol-enriched diet on cardiac performance and oxidative/nitrosative stress, wildtype
and human apoB100 transgenic mice were fed a 2% cholesterol-enriched or a normal diet for 18 weeks. Serum cholesterol and LDL-
cholesterol levels were significantly elevated only in the cholesterol-fed apoB100 transgenic mice, while serum triglycerides were increased
in the transgenic mice fed a normal diet. Cholesterol-enriched diet significantly increased cardiac superoxide generation and NADPH oxidase
expression and activity in apoB100 mice but not in wildtypes. Cardiac NO content and NO synthase activity did not change in either group.
As assessed in isolated working hearts, aortic flow was significantly decreased only in apoB100 transgenic mice fed a cholesterol-enriched
diet. The peroxynitrite decomposition catalyst FeTPPS attenuated the decrease in aortic flow in cholesterol-fed apoB100 mice.
Immunohistochemistry showed elevated nitrotyrosine in the hearts of apoB100 mice fed the cholesterol-enriched diet.
Conclusions: We conclude that hypercholesterolemia but not hypertriglyceridemia leads to increased formation of superoxide and
peroxynitrite, and thereby results in cardiac dysfunction in hearts of human apoB100 transgenic mice.
© 2007 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Atherosclerosis results in coronary heart disease (CHD),
one of the major cause of morbidity and mortality in civilized
societies. The link between elevated cholesterol and CHD
has been clearly established and the National Cholesterol
Education Program clinical guidelines for the treatment of
hypercholesterolemia identify low-density lipoprotein
(LDL) cholesterol as the primary treatment target [1].
Nevertheless, recent research activities identify novel and
independent risk factors for CHD. Hypertriglyceridemia
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 increase the risk of acute coronary events, and some clinical
trials found high serum triglycerides to be an independent
risk factor for cardiovascular disease [2–7].
Althoughthefocusofresearchsofarhasbeenmainlyonthe
vasculareffectsofhyperlipidemia,i.e.arteriosclerosis,itisnow
quite evident that hyperlipidemia exerts direct effects on the
myocardium in addition to the development of atherosclerosis
[8,9]. Intracellular lipid accumulation in cardiomyocytes and
several alterations in the structural and functional properties of
themyocardiumhavebeenobservedinresponse tocholesterol
diet [10–13]. We and others have previously shown that
hyperlipidemia attenuates the cardioprotective effect of
ischemic preconditioning via a mechanism independent from
atherosclerosis and other vascular effects of hyperlipidemia
[8,9,14,15]. Furthermore, we have recently shown that a
moderate hypercholesterolemia combined with a marked
hypertriglyceridemia leads to a moderate contractile dysfunc-
tion in isolated rat hearts [12], and to marked alterations in the
expressionofseveralgenesofvariousfunctionalclustersinthe
myocardium [13]. These results show that hyperlipidemia
exerts complex effects on the myocardium.
Hyperlipidemia is often linked to oxidative/nitrosative
stress in the vasculature and in the myocardium, although the
exact mechanism of such a relationship is yet to be clarified
[9,12,13,16,17]. We have previously shown an increased
formation of peroxynitrite, a toxic reaction product of
superoxide and nitric oxide, in the rat myocardium in
cholesterol-enriched diet-induced hyperlipidemia [12]. Per-
oxynitrite has been reported to induce DNA damage, to
increase lipid peroxidation, and to cause post-translational
modification on proteins (e.g. nitration, oxidation of thiol
groups), thereby activating (e.g. poly-ADP-ribose polimer-
ase, matrix metalloproteinases) or inhibiting (e.g. aconitase,
superoxide dismutase) certain enzymes [18]. These cellular
effects of peroxynitrite may contribute to the development of
contractile dysfunction seen in hyperlipidemic rats, however,
the precise mechanisms leading to increased peroxynitrite
remain to be investigated, and further studies are required to
explore whether hypercholesterolemia or hypertriglyceride-
mia is responsible for the peroxynitrite-mediated detrimental
effect of experimental hyperlipidemia.
Recent advances in the development of genetically
engineered mouse models of hypercholesterolemia may
allow for a more appropriate control for the effect of species-
dependent genetic differences in lipid transport and metab-
olism. Transgenic mice expressing human apolipoprotein B-
100 showed slightly elevated total cholesterol and markedly
elevated triglycerides when compared to wildtype mice fed
normal diet [19]. However, when these human apoB-100
transgenic mice were fed a diet high in fat and cholesterol
serum levels of non-HDL and total cholesterol were further
increased and serum triglycerides were returned to normal
levels [19]. Thus, these mice seem suitable for investigation
of the differential effect of hypercholesterolemia or hyper-
triglyceridemia on cardiac oxidative stress and contractile
function. In addition, the lipoprotein profile of apoB-100
transgenic mice, especially when fed a high-fat diet is similar
to that seen in humans, i.e. higher proportions of VLDL and
LDL fractions compared to HDL [19–21].
Therefore, in order to investigate whether hypercholesterol-
emia per se induces oxidative stress and thereby leads to cardiac
dysfunction in the heart we have used human apoB-100
transgenic or wildtype mice fed either a cholesterol-enriched or
normaldiet.Tofurtherclarifythemechanismofhyperlipidemia-
induced oxidative and nitrosative stress we have systematically
analyzed serum lipid profile, myocardial levels of superoxide
and nitric oxide, the activity and expression of their enzymatic
sources, cardiac function, and the effect of pharmacologic
decomposition of peroxynitrite on cardiac function.
2. Methods
This investigation conforms with the Guide for the Care
andUseofLaboratoryAnimalspublishedbytheUSNational
Institutes of Health (NIH publication No. 85-23, revised
1996) and was approved by the local ethics committee.
2.1. Animals, diets, experimental groups
Transgenic mice overexpressing human apoB-100 protein
were generated as described earlier [22]. Briefly, fertilized
oocytes of C57/B6×CBA F1 females were collected and
injected with the purified P1-phagemid DNA containing the
entire 43 kb human apoB-100 gene, the 19 kb of the 5′ and
the 14 kb of the 3′ flanking genomic sequences [20] in a
concentration of 1 ng/ml, according to a standard technique
[23]. Tail DNA of 10-day-old pups was purified [22], and
integrated transgenes were detected by PCR, using primers
from the 5′ promoter region of human apoB gene [20]. The
expression of human apoB-100 transgene was detected by
using real-time RT-PCR and Western blot analysis. The best-
expressing line (line 485) was selected for further studies.
ApoB-100 transgenic F1 and control wildtype F1 mice
were backcrossed twice with C57/B6 inbred mice in order to
get closer to the atherosclerosis susceptible C57/B6 genetic
background [24,25]. Wildtype and homozygous apoB-100
transgenic mice of either sex, housed in a room maintained at
12 h light/dark cycles and a constant temperature of 22±
2 °C, were fed either a laboratory chow enriched with 2%
cholesterol or a standard chow for 17–19 weeks. At the end
of the diet period, hearts were isolated for measurement of
cardiac function and biochemical parameters, and aortas
were removed for lipid staining. Some tissue was embedded
in OCT for immunohistochemistry and histology studies (for
details see Supplementary materials). Blood samples were
collected from separate animals after 30 min fasting and
stored at −70 °C until assayed for serum lipids, glucose, and
malondialdehyde.
In order to check if peroxynitrite causes cellular damage
and myocardial dysfunction due to hypercholesterolemia,
separate groups of transgenic mice fed cholesterol-enriched
or normal diet were injected twice intraperitoneally with
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 2×20 mg/kg FeTPPS (5,10,15,20-tetrakis-[4-sulfonatophe-
nyl]-porphyrinato-iron[III]), a peroxynitrite decomposition
catalyst, 24 h and 1 h prior to isolation of the hearts [12].
2.2. Determination of serum lipids and glucose
Serum lipids including total cholesterol, triglycerides,
LDL and HDL cholesterol, as well as glucose levels were
measured in triplicate, using commercially available color-
imetric assay kits applying enzymatic determinations
(Diagnosticum Ltd., Budapest, Hungary) adapted to 96-
well plates. Accuracy of the assays was monitored by using
Standard Lipid Controls (Sentinel, Milan, Italy). Results are
expressed as mmol/l of serum.
To analyze the ratios of α, pre-β, and β-lipoproteins in the
serum of wildtype and transgenic mice fed cholesterol-
enriched or normal diet, lipoproteins were separated on
agarose gel, using Paragon Electrophoresis System Lipo-
protein Electrophoresis Kit (Beckman Coulter, Fullerton,
CA) according to the manufacturer's instructions.
2.3. Measurement of serum malondialdehyde levels
In order to measure the level of systemic lipid peroxida-
tion serum malondialdehyde was assayed spectrophotomet-
rically at 535 nm as described previously [12]. Results are
expressed as nmol MDA/mL serum.
2.4. Measurement of superoxide production
To assess if hypercholesterolemia or hypertriglyceridemia
leads to increased formation of cardiac superoxide, in separate
experiments,superoxideproductioninfreshlymincedventricles
was assessed by lucigenin-enhanced chemiluminescence in
wildtype and apoB-100 transgenic mice fed either normal or
cholesterol-enriched diet as described previously [12,26].
Approximately 50 mg cardiac tissue was placed in Krebs–
Henseleit buffer containing 5 μmol/L lucigenin. Chemilumi-
nescence was measured at room temperature in a liquid
scintillation counter (Tri-Carb 2100TR, Packard Instrument
Company, Meriden, CT). Cardiac superoxide production was
expressed as counts per min/mg wet tissue weight.
2.5. In situ detection of superoxide
In situ detection of superoxide was performed by confocal
laser scanning microscopy using the oxidative fluorescent
dye dihydroethidium. Dihydroethidium is freely permeable
to cell membranes and fluorescing red when oxidized to
ethidium by superoxide. Fresh frozen heart sections (30 μm)
were incubated with 10
−6 mol/L dihydroethidium (Sigma) in
PBS (pH 7.4; 37 °C; 30 min) in a dark humidified container.
Fluorescence in heart sections was then detected by an LSM
410 confocal microscope with a 590-nm long-pass filter.
Images of sections treated with saline (negative control) were
measured first.
2.6. Measurement of cardiac NO by electron spin resonance
spectroscopy (ESR)
To measure cardiac NO content directly, in vivo spin-
trapping of NO was applied, followed by ESR analysis of
ventricular tissue samples as described [27,28]. The spin trap
diethyl-dithio-carbamate (DETC, 500 mg/kg), 50 mg/kg
FeSO4, and 200 mg/kg sodium citrate were administered i.p.
under ether anesthesia. Thirty minutes after injections of
DETC and a mixture of FeSO4 and citrate, ventricular
samples were placed into quartz ESR tubes, frozen in liquid
nitrogen until assayed for ESR spectra of the NO–Fe
2+
(DETC)2 complex. Fe
2+(DETC)2 has high affinity for NO
while forming NO–Fe
2+(DETC)2. ESR spectra was recorded
with a Bruker ECS106 (Rheinstetten, Germany) spectrom-
eter at a temperature of 160 K as described [27,28].
2.7. Isolated working mouse heart
Cardiac performance was assessed in isolated working
mousehearts,asdescribed[29].Heparinizedmice(100Ui.p.)
were anesthetized with diethyl ether. Hearts were then
isolated, the aorta was cannulated and initially perfused in
Langendorff mode (at a constant pressure of 60 mmHg,
37 °C) with Krebs–Henseleit buffer containing (in mmol/L)
118 NaCl, 25 NaHCO3, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4,
1.75 CaCl2, and 11.1 glucose, oxygenated with 95% O2–5%
CO2 (pH=7.4). Meanwhile the left atrium was cannulated
and the perfusion was then switched to a recirculating
working mode (10 min, 37 °C, preload 15 mmHg, afterload
60 mmHg). Coronary flow, aortic flow, and left ventricular
pressure were measured at the end of working perfusion.
Cardiac work was calculated as cardiac output×peak left
ventricular systolic pressure. At the end of perfusion the
hearts were snap frozen in liquid nitrogen and stored at
−70 °C until they were used for biochemical assays.
2.8. Measurement of cardiac activities and expression of
NAD(P)H oxidase, superoxide dismutase (SOD), and NOS
The frozen ventricles were ground at the temperature of
liquid nitrogen and homogenized as described [29]. Protein
concentration was measured in the homogenates by the
bicinchoninic acid method using bovine serum albumin as a
reference standard (Sigma St. Louis, MO).
NAD(P)H-stimulated superoxide production in freshly
prepared ventricular homogenates was assessed by luci-
genin-enhanced luminescence as described [29] with some
modifications. To estimate background levels of superoxide
formation ventricular homogenate (30 μL) was added to
1 mL Krebs–Henseleit–HEPES buffer containing 5 μmol/L
lucigenin. Chemiluminescence was measured with liquid
scintillation counter every 15 s for 5 min and the last 6
readings were averaged. To measure NAD(P)H-stimulated
superoxide generation, either 100 μmol/L NADH or
100 μmol/L NADPH were added to the tubes and changes
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 in luminescence after each addition were measured. The
background luminescence was subtracted from the readings
with NADH or NADPH. Values were standardized to the
amount of protein present and expressed as counts per
minute/mg protein. NADH or NADPH alone did not evoke
lucigenin chemiluminescence in the absence of homogenate.
To monitor gene expression changes of Nox1, Nox2 and
Nox4, quantitative real-time PCR (QRT-PCR) reactions [30]
and Western blot analysis were done (for details see
Supplementary materials).
To estimate the level of the main enzymatic defense
mechanism against superoxide myocardial SOD activity was
determined [26]. Total activity of SOD in ventricular
homogenate was measured by a spectrophotometric assay
using a kit (Randox Laboratories, UK) according to the
instructions of the manufacturer.
NOS activities in cardiac homogenate of frozen ventric-
ular tissue were determined from the rate of conversion of L-
[
14C]arginine to L-[
14C]citrulline as described [26]. Samples
were incubated for 60 min at 37 °C in the presence or
absence of EGTA (1 mmol/L) plus NG-monomethyl-L-
arginine (1 mmol/L) to determine the level of total NOS
activities expressed in pmol/min/mg protein.
2.9. Statistical analysis
Data were expressed as means±SEM and analysed with
one-way ANOVA followed by Tukey's post-hoc test.
pb0.05 was used as the criterium for indicating a statistically
significant difference.
3. Results
3.1. Validation of human apoB-100 expression
Expression of human apoprotein B-100 was validated in
the liver and heart of both wildtype and human apoB-100
transgenic mice. Human apoprotein B-100 showed a marked
Fig. 1. Expression of human apoB-100 protein in the liver and heart of
transgenic and wildtype mice.
Fig. 2. Serum total cholesterol (A), serum triglycerides (B), LDL-cholesterol (C), HDL-cholesterol (D), lipoprotein electrophoresis (E), and serum glucose (F)
levels in apoB100 and WT (Cont) mice fed either cholesterol-enriched (chol) or normal diet. Results are means±SEM (n=5–8 in each group). ⁎Pb0.05 vs.
controls.
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 expression in both the liver and the heart of transgenic
animals, without being expressed in wildtype mice (Fig. 1).
3.2. Serum lipids
Neither cholesterol-enriched diet, nor apoB-100 trans-
gene affected serum total cholesterol when compared to
normal diet-fed wildtype mice (Fig. 2A). However, serum
cholesterol was increased significantly due to cholesterol-
enriched diet in the apoB-100 transgenic animals (Fig. 2A,
n=7–8 in each group). Similarly, the level of LDL
cholesterol was increased significantly only in the apoB-
100 transgenic mice fed cholesterol-enriched diet (Fig. 2C,
n=5–6 in each group). On the other hand, neither of the
treatments affected HDL cholesterol levels significantly
(Fig. 2D, n=5–6 in each group). ApoB-100 transgene
markedly increased the level of triglycerides in the serum
compared to normal diet-fed wildtypes, however, serum
triglycerides were reduced significantly by cholesterol in
transgenic mice (Fig. 2B, n=7–8 in each group).
To determine the lipoprotein distribution in the transgenic
or wildtype mice fed normal or cholesterol-enriched diet,
plasma samples were analyzed by gel electrophoresis
(Fig. 2E, Table 1). In the plasma of the apoB-100 transgenic
mice, the amount of β-migrating lipoproteins increased
dramatically with a parallel decrease in the α fraction
(pb0.05, n=7–8 in each group). Cholesterol feeding slightly
but not significantly increased preβ-migrating lipoproteins
in wildtypes (Table 1), while caused only a slight shift of the
β-fraction towards the preβ-fraction in the transgenic
animals (Fig. 2E) without affecting the level of β-fraction.
To determine if cholesterol-enriched diet influenced
carbohydrate metabolism, serum glucose levels were
measured. No significant alterations in serum glucose
concentration were detected in either groups (Fig. 2F).
3.3. Systemic oxidative stress
As a marker of systemic lipid peroxidation due to
oxidative stress, serum malondialdehyde levels were deter-
mined in apoB-100 transgenic and wildtype mice fed either
Table 1
Distribution of lipoproteins in the sera of wildtype (Cont) and apoB100
transgenic mice fed normal or cholesterol-enriched diet
Control Control cholesterol apoB tg apoB tg cholesterol
α 67±5% 63±3% 35±4%⁎ 40±3%⁎
pre-β 24±5% 37±3% 31±5% 34±6%
β 10±3% 1±1% 31±4%⁎ 26±6%⁎
⁎pb0.05 vs. corresponding wildtype controls; n=7–8.
Fig. 3. Serum malondialdehyde levels (MDA) as indicators of lipid peroxidation (A), cardiac superoxide production (B), myocardial NADPH oxidase activity
(C), myocardial superoxide dismutase (SOD) activity (E), representative western blot of cardiac NADPH oxidase 1 (Nox1) (D), and cardiac Nox 1 (F) in
apoB100 and WT (Cont) mice fed either cholesterol-enriched (chol) or normal diet. Results are means±SEM (n=3–8). ⁎Pb0.05 vs. controls.
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 cholesterol-enriched or normal diet (n=5–6 in each group).
Malondialdehyde levels were significantly increased in
cholesterol-fed transgenic animals when compared to wild-
type ones fed normal diet (Fig. 3A).
3.4. Cardiac superoxide, NADPH oxidase and superoxide
dismutase activity
Cardiac superoxide formation was estimated in freshly
minced heart tissue by lucigenin-enhanced chemilumines-
cence. Cardiac superoxide was markedly increased by
cholesterol-enriched diet in the apoB-100 transgenic mice,
but not in wildtypes (Fig. 3B). ApoB transgene alone did not
change cardiac superoxide in mice fed normal diet (Fig. 3B).
In order to confirm these data, we have detected superoxide
in situ. Dihydroethidium staining of heart slices showed
increased fluorescence due to cholesterol-enriched diet,
especially in the apoB-100 transgenic animals (Fig. 4). The
transgene alone did not affect superoxide-induced cardiac
dihydroethidium fluorescence (Fig. 4).
To determine possible sources of cardiac superoxide, the
activity of NAD(P)H oxidase and XOR was measured from
heart homogenates. Cholesterol-enriched diet significantly
increased the activity of NADPH oxidase in human apoB-
100 transgenic mice without having an effect in wildtype
ones (Fig. 3C, n=6–8 in each group). Activities of neither
NADH oxidase nor XOR have changed significantly in any
of the treatment groups (n=5–6 in each group, data not
shown). Since we found increased cardiac activity of
NADPH oxidase in the cholesterol-fed apoB-100 transgenic
mice, we have further looked at the expression of NADPH
oxidase 1 (Nox1), Nox2 and Nox4 by quantitative real-time
PCR (n=4 in each group). Cholesterol-enriched diet
significantly increased 1.75 times the cardiac expression of
NADPH oxidase 1 mRNA in the apoB-100 transgenic mice
while having no effect in wildtype ones (data not shown). The
expression of Nox 2 and Nox4 did not change significantly in
eithergroup(datanotshown).Westernblotanalysisofcardiac
homogenates showed increased Nox1 protein level in
cholesterol-fed apoB100 mice (Fig. 3D, F, n=3 in each
group).
To estimate the activity of the most important enzymatic
antioxidant mechanism against superoxide, total cardiac
superoxide dismutase activity was determined. Neither
apoB-100 transgene, nor cholesterol-enriched diet affected
Fig. 4. Images of cardiac slides from wildtype (A, B) and human apoB100 transgenic mice (C, D) fed either normal (A, C) or cholesterol-enriched (B, D) diet
following treatment with dihydroethidium (1 μM).
Fig. 5. Myocardial NO content (A), and NOS activity (B) in apoB100 and
WT (Cont) mice fed either cholesterol-enriched (chol) or normal diet.
Results are means±SEM (n=5–7).
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 total superoxide dismutase activity in the mouse heart
(Fig. 3E, n=6–8 in each group).
3.5. Cardiac nitric oxide content, NOS activity
To study if cholesterol-enriched diet or human apoB-100
transgene affects nitric oxide content in mouse hearts,
electron spin resonance spectroscopy following in vivo spin
trapping was applied (n=5–6 in each groups). Cardiac nitric
oxide content did not change due to apoB-100 transgene or
cholesterol-enriched diet in either groups (Fig. 5A).
Moreover, cardiac activity of NOS, the enzyme responsible
for the endogenous synthesis of NO, was not altered in either
groups (Fig. 5B, n=5–7 in each groups).
3.6. Myocardial dysfunction and peroxynitrite
Parameters of cardiac performance are shown on Fig. 6.
and Table 2. Neither the presence or absence of the apoB-100
gene, nor the cholesterol content of the diet had any
significant effect on heart rate, coronary flow, left ventricular
peak systolic pressure, or ±dp/dtmax (Table 2). Aortic flow
and cardiac work were determined to estimate basal pumping
capacity of the heart. The apoB-100 transgene did not alter
aortic flow and cardiac work when the animals received
normal diet (Fig. 6). However, cholesterol-enriched diet
significantly deteriorated aortic flow and cardiac work in the
human apoB-100 transgenic mice without having an effect in
wildetypes (Fig. 6, n=7–9 in each group).
To test if peroxynitrite is involved in cardiac dysfunction
induced by cholesterol-enriched diet in apoB-100 transgenic
mice, a peroxynitrite decomposition catalyst, FeTPPS, was
injected to transgenic mice 24 and one hour prior to isolation
of the hearts and assessment of cardiac performance.
FeTPPS-pretreatment significantly improved aortic flow
deteriorated by cholesterol-enriched diet in apoB-100
transgenic mice (Fig. 6, n=5–7 in both groups).
To further prove that cholesterol-enriched diet leads to
increased nitrosative stress in apoB100 transgenic mice we
havelookedatnitrotyrosineimmunostainingofheartsections,
and found elevated tissue level of nitrotyrosine in the
cholesterol fed transgenic mice (Fig. 6, n=3 in each groups).
Hematoxylin-eosin and Crossman's trichrome staining
for histology did not reveal any pathological changes in
either groups (data not shown).
4. Discussion
In this study, we have systematically analyzed the plasma
lipid, lipoprotein, and MDA levels, as well as the cellular
mechanisms of cardiac oxidative and nitrosative stress, along
with the estimation of myocardial contractile function in
human apoB100 transgenic and WT mice fed normal or
high-cholesterol diet. We have shown here that in apoB100
transgenic mice hypercholesterolemia induced by cholester-
ol-enriched diet increases cardiac oxidative/nitrosative stress
Fig. 6. Aortic flow (A) and cardiac work (B) in isolated working hearts of
apoB100 transgenic and WT (Cont) mice fed either cholesterol-enriched
(chol) or normal diet when pretreated or not with the peroxynitrite
decomposition catalyst FeTPPS. Cardiac nitrotyrosine level in wildtype
and apoB100 transgenic mice fed normal or cholesterol-enriched diet as
assessed by immunohistochemistry (C) Results are means±SEM (n=5–7).
⁎Pb0.05 vs. controls.
Table 2
Hemodynamic data in isolated working mouse hearts
Control Control cholesterol apoB tg apoB tg cholesterol apoB tg FeTPPS apoB tg cholesterol FeTPPS
Body weight (g) 26.8±1.7 26.5±1.8 24.1±0.6 28.7±1.3 24.8±2.0 27.0±1.3
Heart rate (bpm) 327±18 334±17 325±13 334±18 312±22 331±17
Coronary flow (ml/min/g bw) 0.12±0.01 0.12±0.01 0.14±0.02 0.13±0.01 0.14±0.02 0.14±0.02
Cardiac output (ml/min/g bw) 0.37±0.03 0.37±0.03 0.42±0.03 0.25±0.03⁎ 0.43±0.06 0.41±0.03
LVPSP (kPa) 13.2±0.2 12.6±0.4 13.6±0.4 12.7±0.5 14.4±0.4 13.4±0.3
+dp/dtmax (kPa/s) 614±33 661±32 665±26 617±32 663±18 648±27
−dp/dtmax (kPa/s) 413±17 463±28 487±22 455±33 513±29 506±30
⁎pb0.05 vs. corresponding wildtype and apoB transgenic controls; n=7–9.
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 thereby leading to cardiac dysfunction, which can be
prevented by pharmacologic attenuation of cardiac nitrosa-
tive stress. Furthermore, this is the first demonstration that
hypercholesterolemia but not hypertriglyceridemia is re-
sponsible for the hyperlipidemia-induced, peroxynitrite-
mediated cardiac dysfunction and that increased cardiac
expression of NADPH oxidase is the major source of
increased oxidative stress in hypercholesterolemia.
In our present studies, cholesterol-enriched diet resulted
in an increase in serum total cholesterol and LDL cholesterol
levels in the human apoB-100 transgenic mice without
having an effect in wildtypes. HDL cholesterol did not
change significantly between the groups. Similarly to
previous findings [19,21], serum triglycerides were mark-
edly elevated in apoB-100 transgenics fed normal diet
compared to wildtype values. Cholesterol-enriched diet did
not have an effect on serum triglycerides in wildtype mice,
however, it did reduce elevated triglycerides back to normal
values in apoB-100 transgenic animals. This unique lipid
profile makes our transgenic model a suitable tool for the
investigation of the distinct effects of hypercholesterolemia
(in cholesterol-fed apoB-100 transgenic mice) and hyper-
triglyceridemia (in apoB-100 transgenic mice fed normal
diet) on the heart. Another useful feature of this model is the
more “human-like” distribution of lipoproteins in the
cholesterol-fed transgenic mice than seen in wildtypes. In
accordance with previous studies [19,31] we have found an
increased LDL cholesterol/HDL cholesterol ratio in the
cholesterol-fed apoB-100 mice that is more characteristic for
the human rather than the murine lipid profile.
It is well known that hyperlipidemia increases vascular
oxidative stress [32,33]. Here we have found that oxidative/
nitrosative stress in the heart was increased in cholesterol-fed
apoB-100 mice compared to wildtypes. In order to assess
cardiac oxidative/nitrosative stress, we have systematically
analyzed myocardial formation of superoxide (measured by
lucigenin chemiluminescence and dihydroethidium stain-
ing), NO, and peroxynitrite (by nitrotyrosine immunohisto-
chemistry), as well as the activities and expression of major
enzymatic sources of these species (xanthin oxidoreductase,
NAD(P)H oxidase, and NOS), and the most relevant
antioxidant enzyme activities (SOD). In agreement with
our previous study in a rat model of hyperlipidemia [12],w e
have shown here an increase in cardiac superoxide
production. This is the first demonstration that both the
expression and activity of NADPH oxidase is responsibe, at
least in part, for the increased superoxide production seen in
cholesterol-fed apoB100 transgenic mice. We have further
shown that increased oxidative stress was associated with a
significant myocardial dysfunction in the transgenic mice fed
cholesterol. The mechanism by which superoxide has
contributed to the cardiac dysfunction likely involves the
formation of the cytotoxic species, peroxynitrite. Patholog-
ical conditions resulting in increased production of NO,
superoxide, or both often leads to increased formation of
peroxynitrite, which causes cellular damage [34–36].W e
have previously reported that hyperlipidemia (marked
hypertriglyceridemia and moderate hypercholesterolemia)
induced by cholesterol-enriched diet resulted in enhanced
formation of peroxynitrite in rat hearts [12]. Our present
study shows that cholesterol-enriched diet in apoB-100
transgenic mice leads to increased myocardial oxidative
stress and cardiac dysfunction. We have further shown here
that the peroxynitrite decomposition catalyst FeTPPS
improved cardiac contractile function deteriorated by
cholesterol-enriched diet in apoB-100 transgenic mice,
indicating that formation of peroxynitrite in these mice
exerts a deleterious effect on cardiac function. Our data also
indicates that the increased superoxide formation is respon-
sible for the increased peroxynitrite in these hearts, since
neither the activity of NOS, nor cardiac NO content showed
any change among the treatment groups.
In this study we have also determined if the development
of myocardial oxidative/nitrosative stress and cardiac dys-
function is affected by either hypercholesterolemia or
hypertriglyceridemia. Cardiac formation of superoxide as
well as the activity and expression of NADPH oxidase
increased parallel with serum cholesterol but independent of
serum triglyceride levels. Similarly, in our study, hypercho-
lesterolemia but not hypertriglyceridemia seemed to be
associated with cardiac dysfunction. This likely means that
hypertriglyceridemia per se does not affect the myocardium
directly. In our study, we have not found an association
between the level of serum cholesterol or triglycerides and
changes in the activities of XOR, NADH oxidase, or SOD.
Thus, it seems a plausible explanation that cholesterol-
enricheddiet-inducedhypercholesterolemiainducesNADPH
oxidase and increases cardiac superoxide, thereby leading to
increased peroxynitrite production, which results in cardiac
dysfunction. Increased NAD(P)H oxidase-mediated super-
oxide generation seen in vessels of hypercholesterolemic
subjects [2,37–39] further supports our present results.
Although the direct link between serum cholesterol and the
activation of NADPH oxidase is not entirely clear in the
myocardium one possible mechanism has been described for
the activation of the phagocyte NADPH oxidase [40].T h i s
paper suggest that cholesterol-enriched microdomains in the
membraneacttorecruitand/ororganizethecytosolicNADPH
oxidase factors inthe assemblyof the active NADPH oxidase.
In summary, cardiac oxidative/nitrosative stress induced
by hypercholesterolemia but not hypertriglyceridemia leads
to myocardial dysfunction. Consequently, lowering of serum
cholesterol or attenuation of oxidative/nitrosative stress by
pharmacological tools may be effective potential targets to
protect the heart in hypercholesterolemia.
It is plausible to speculate that lowering of serum
cholesterol by pharmacological tools may protect the heart
against oxidative and nitrosative stress in hypercholesterol-
emia, however, it needs further investigations. Some statins
have been shown to decrease vascular oxidative and
nitrosative stress, and we have previously found that e.g.
inhibition of the mevalonate pathway did not influence
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 cardiac nitric oxide synthesis [41]. Nevertheless, a number of
clinical trials and animal experiments have shown the
beneficial effects of cholesterol-lowering drugs in the
prevention of ischemic heart diseases [42,43].
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